Splenic infarction due to multiple left ventricular mobile thrombi in hypereosinophilic endomyocarditis.

McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987–2991. 29. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308–1320. 30. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778–1785. 31. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873–879. 32. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:697–704. 33. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992;86: 730–740. 34. Connolly SJ. Use and misuse of surrogate outcomes in arrhythmia trials. Circulation 2006;113:764–766. 35. Hlatky MA. Evidence-based use of cardiac procedures and devices. N Engl J Med 2004;350:2126–2128.